Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT1 trial in primary thrombocythaemia risk groups
ISRCTN72251782Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Jul 1997
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of aspirin, hydroxyurea and anagrelide in thrombocythemia (5 arms), sponsored by Medical Research Council. Primary endpoints: Vascular occlusion, Haemorrhagic events and 4 more. Started Jul 1997; status: completed.
02
Drugs
aspirinhydroxyureaanagrelide
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on ISRCTN72251782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72251782.